A 22-year-old Japanese man was diagnosed with Sézary syndrome with large cell transformation. His skin lesions persisted after treatment with 7 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), psoralen and ultraviolet light A, and total skin electron beam irradiation. He subsequently underwent allogeneic bone marrow transplantation by reduced-intensity conditioning from a human leukocyte antigen-identical unrelated donor. He developed grade II of acute graft-versus-host disease and extensive-type chronic graft-versus-host disease. He has no signs of disease 36 months after the transplantation. The prognosis of patients with advanced stage of mycosis fungoides or Sézary syndrome is very poor. Allogeneic hematopoietic stem cell transplantation, especially by reduced-intensity conditioning, is expected to become a curative treatment option, and graft-versus-tumor effect might play a critical role for sustained remission.

Keywords:
Allogeneic hematopoietic stem cell transplantation, Graft-versus-tumor effect, Reduced-intensity regimen, Sézary syndrome
1.
Wieselthier JS, Koh HK: Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990;3:381–401.
2.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange G, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJLM: WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
3.
Whittaker SJ, Foss MF: Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007;33:146–160.
4.
Ralfkiaer E, Jaffe ES: Mycosis fungoides and Sézary syndrome; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 216–220.
5.
Kim YH, Hoppe RT: Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999;26:276–289.
6.
Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, Phelps R, O’Connor T, Trepel JB, Cotelingam JD, Gazdar AF, Minna JD, Bunn PA Jr: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372–382.
7.
Fraser-Andrewa EA, Wookford AJ, Russell-Jones R, Seed PT, Whittaker SJ: Detection of a peripheral blood T cell clone in an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000;114:117–121.
8.
Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, Chilcott S, Spittle M, Grieve RJ, Stewart S, Apperley JF, Russell-Jones R: T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001;114:624–631.
9.
Koeppel MC, Stoppa AM, Resbeut M, Blaise D, Coignet M, Coulier L, Maraninchi D, Sayag J: Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol 1994;74:331–332.
10.
Molona A, Nademanee A, Arber DA, Forman SJ: Remission of refractory Sézary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1991;5:400–404.
11.
Burt RK, Guitart J, Traynor A, Link C, Rosen ST, Pandolfino T, Kuzel TM: Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000;25:111–113.
12.
Masood N, Russell KJ, Olerud JE, Sabath DE, Sale GE, Doney KC, Flowers MDE, Fefer A, Thompson JA: Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002;47:140–145.
13.
Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt RK: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002;138:1359–1365.
14.
Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, Venegoni L, Corbellino M, Annaloro C, Robbiolo L, Della Volpe A, Alessi E, Lambertenghi Deliliers G: Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 2003;31:663–666.
15.
Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM: Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:521–525.
16.
Molina A, Zain J, Arber DA, Angelopolou M, O’Donnell M, Murata-Collins J, Forman SJ, Nademanee A: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. J Clin Oncol 2005;23:6163–6171.
17.
Bunn PA, Lamberg SI: Reports of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725–728.
18.
Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B: Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol 2006;1:685–694.
19.
Russell-Jones R, Spittle MF: Management of cutaneous lymphoma. Baillieres Clin Haematol 1996;9:743–767.
20.
Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, Parlette HL III, Anderson MJ, Sausville EA: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784–1790.
21.
Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J: Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann NY Acad Sci 2001;941:147–154.
22.
Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, Vonderheid EC, Brodsky I: Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991;7:133–137.
23.
Sterling JC, Marcus R, Burrows NP, Roberts SO: Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 1995;20:73–75.
24.
Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Vérola O, Brandely M, Morel P, Gisselbrecht C: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574–579.
25.
Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63–73.
26.
Evans AV, Wood BP, Scarisbrick JJ, Fraser-Andrews EA, Chinn S, Dean A, Watkins P, Whittaker SJ, Russell-Jones R: Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response. Blood 2001;98:1298–1301.
27.
Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL: Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998;76:304–311.
28.
Zeng J, Müller-Berghaus J, Nguyen XD, Klüter H, Schönhaber H, Song M, Schwinn N, Schadendorf D, Goerdt S, Eichmüller S, Dippel E: Identification of HLA class I dependent immunogenic peptides from clonotypic TCRβ expressed in cutaneous T-cell lymphoma. Int J Cancer 2006;119:2476–2480.
29.
Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, Russell-Jones R: Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001;97:624–630.
30.
Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R: Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150–1159.
31.
Thangavelu M, Finn WG, Yelavarthi KK, Roenigk HH Jr, Samuelson E, Peterson L, Kuzel TM, Rosen ST: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood 1997;89:3371–3377.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.